InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,457.58
(
0.91%
)
US TECH 100
18,079.63
(
0.74%
)
Dow Jones
40,779.12
(
1.07%
)
Brent Oil
71.72
(
0.26%
)
Bitcoin
56,462.82
(
2.91%
)

Replies to post #250609 on Elite Pharmaceuticals Inc (ELTP)

Replies to #250609 on Elite Pharmaceuticals Inc (ELTP)
icon url

jour_trader

04/12/17 9:26 AM

#250619 RE: mrwrn2010 #250609

Was in one of the cc scripts. Forgot about it and refreshed my memory on several points last weekend. I'll track it down and use direct quote & reference.
icon url

jour_trader

04/12/17 9:47 AM

#250622 RE: mrwrn2010 #250609

Q3 2016 call CEO stated:

“The clinical results for SequestOx, now that we disclosed what the product is, will be presented at various pain conferences this year. So far we have two -- possibly three lines up for these presentations act. We have now announced that SequestOx, ELI-200 are oxycodone, the current market for the generic part is $400 million.”

Why would he reference the generic market potential? SequestOx will be a branded IR. What am I missing here?